Education/Working Experience
1988~1993      bachelor of Dalian Medical University
1999~2002      master of Dalian Medical University
2004.02~2004.07 further education at Cancer hospital of Chinese Academy of           Sciences
2013.08~2014.02  visiting scholar at Mayo Clinic
1993~up to now   work in The Second Hospital of Dalian Medical University
Participation in the Academic Community
Vice-chairmen of Liaoning Cancer Society of Cancer and Palliative Rehabilitation Committee;
Standing committee of committee of Liaoning Association of cancer chemotherapy;
Committee member of Liaoning Provincial Medical Association Cancer Branch;
Committee member of Chinese Society for Gerontology and Geriatrics Cancer Rehabilitation;
Committee member of China Healthcare International Exchange Association Cancer Palliative Treatment and Humanistic Care Branch
Publication
1.Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L Oncotarget, 2015 Vol. 6, No. 32 33279-89 Chengli Song 1,* , Qiang Xu 1,* , Kui Jiang 1 , Guangyu Zhou 1 , Xuebin Yu 1 , Lina Wang 1 ,Yuting Zhu 1 , Liping Fang 1 , Zhe Yu 1 , Jiing-Dwan Lee 2 , Shi-Cang Yu 3 , Qingkai Yang 1
2.P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth，Oncotarget，2016 Vol. 7, No. 12，15135-15149，Xiaokun Gang1,2,*, Yinhui Yang2,3,*, Jian Zhong2, Kui Jiang2,4, Yunqian Pan2, R. Jeffrey Karnes5, Jun Zhang6, Wanhai Xu3, Guixia Wang1, Haojie Huang2,5,7
3.Jumonji AT-rich interactive domain 1B over expression is associated with the development and progression of glioma , Liping Fang, Jiuhan Zhao, Dan Wang, Liyu Zhu, Jian Wang, Kui Jiang Int J Mol Med. 2016 July; 38(1): 172–182. Published online 2016 May 30. doi: 10.3892/ijmm.2016.2614
4.Construction of a Murine Phage Fab Library Against MRP1/ABCC1 of Human Breast Carcinoma, Life Science Research, 2014,(04):338-343. ZHANG Xue-mei1, ZHAO Cai-hong1, LI Jun1, LUO Xiao2, JIANG Kui2*;
5.Influence factors of aromatase inhibitor-related arthralgia, Chinese Journal of New Drugs, 2015,(06):664-668,DONG Xin-yue1，ZHU Li-yu2，YANG Xiao-yan3，LIU Fang3，FANG Li-ping3，YAO Lu-lu3， JIANG Kui3
Research Projects/Grants
Host two projects:
1.Clinical study of intracranial immune targeting radiotherapy combined with radiofrequency ablation and interventional therapy for advanced liver cancer;
2.Scientific demonstration of core reagents;
Join in two projects:
1.Feasibility study of RAD18 gene therapy in triple negative breast cancer—the third one;
2.Natural Science Foundation of Liaoning—Expression and prognosis of LGR5, ALDH1 and CD133 in drug-resistant ovarian cancer—the second one
Admission Plan/Requirements 
Have a good ability in English listing，speaking，reading and writing.